Correlation | 3 mg/kg, n = 99 | 6 mg/kg, n = 104 | 10 mg/kg, n = 104 | |||
---|---|---|---|---|---|---|
Coefficient | p | Coefficient | p | Coefficient | p | |
With SDAI at W54 | ||||||
TJC28 at W14 | 0.585 | < 0.0001 | 0.401 | < 0.0001 | 0.429 | < 0.0001 |
SJC28 at W14 | 0.465 | < 0.0001 | 0.420 | < 0.0001 | 0.278 | 0.0042 |
CRP at W14 | 0.475 | < 0.0001 | 0.385 | < 0.0001 | 0.378 | < 0.0001 |
PtGA at W14 | 0.486 | < 0.0001 | 0.526 | < 0.0001 | 0.394 | < 0.0001 |
PGA at W14 | 0.534 | < 0.0001 | 0.566 | < 0.0001 | 0.300 | 0.0020 |
Serum IFX level at W6* | −0.194 | 0.0544 | −0.420 | < 0.0001 | −0.355 | 0.0002 |
Serum IFX level at W10*† | −0.313 | 0.0016 | −0.449 | < 0.0001 | −0.365 | 0.0002 |
Serum IFX level at W14* | −0.246 | 0.0142 | −0.448 | < 0.0001 | −0.385 | < 0.0001 |
With DAS28-CRP at W54 | ||||||
TJC28 at W14 | 0.568 | < 0.0001 | 0.454 | < 0.0001 | 0.404 | < 0.0001 |
SJC28 at W14 | 0.425 | < 0.0001 | 0.475 | < 0.0001 | 0.238 | 0.0151 |
CRP at W14 | 0.475 | < 0.0001 | 0.456 | < 0.0001 | 0.389 | < 0.0001 |
PtGA at W14 | 0.490 | < 0.0001 | 0.598 | < 0.0001 | 0.395 | < 0.0001 |
PGA at W14 | 0.500 | < 0.0001 | 0.607 | < 0.0001 | 0.358 | 0.0002 |
Serum IFX level at W6* | −0.232 | 0.0212 | −0.466 | < 0.0001 | −0.384 | < 0.0001 |
Serum IFX level at W10*† | −0.341 | 0.0005 | −0.493 | < 0.0001 | −0.406 | < 0.0001 |
Serum IFX level at W14* | −0.297 | 0.0028 | −0.484 | < 0.0001 | −0.432 | < 0.0001 |
With HAQ at W54 | ||||||
TJC28 at W14 | 0.362 | 0.0002 | 0.370 | 0.0001 | 0.420 | < 0.0001 |
SJC28 at W14 | 0.277 | 0.0055 | 0.316 | 0.0011 | 0.145 | 0.1411 |
CRP at W14 | 0.255 | 0.0109 | 0.302 | 0.0018 | 0.251 | 0.0100 |
PtGA at W14 | 0.501 | < 0.0001 | 0.573 | < 0.0001 | 0.354 | 0.0002 |
PGA at W14 | 0.397 | < 0.0001 | 0.503 | < 0.0001 | 0.365 | 0.0001 |
Serum IFX level at W6* | −0.062 | 0.5400 | −0.106 | 0.2849 | −0.213 | 0.0298 |
Serum IFX level at W10*† | −0.180 | 0.0744 | −0.183 | 0.0626 | −0.243 | 0.0135 |
Serum IFX level at W14* | −0.117 | 0.2474 | −0.177 | 0.0723 | −0.280 | 0.0039 |
With ΔTSS at W54‡ | ||||||
TJC28 at W14* | −0.052 | 0.6320 | 0.053 | 0.6150 | 0.013 | 0.8975 |
SJC28 at W14* | −0.037 | 0.7342 | 0.079 | 0.4551 | 0.028 | 0.7876 |
CRP at W14* | 0.239 | 0.0269 | 0.122 | 0.2479 | 0.192 | 0.0625 |
PtGA at W14* | 0.192 | 0.0761 | 0.170 | 0.1045 | 0.045 | 0.6667 |
PGA at W14* | 0.249 | 0.0206 | 0.242 | 0.0199 | 0.132 | 0.2027 |
Serum IFX level at W6* | −0.141 | 0.1946 | −0.143 | 0.1736 | −0.103 | 0.3205 |
Serum IFX level at W10* | −0.177 | 0.1028 | −0.174 | 0.0973 | −0.046 | 0.6593 |
Serum IFX level at W14* | −0.158 | 0.1460 | −0.127 | 0.2275 | −0.057 | 0.5832 |
Correlations of components of disease activity at W14 and serum IFX levels at W6 to W14 with disease activity, HAQ score and ΔTSS at W54 were calculated using Pearson correlation coefficient or
↵* Spearman rank correlation coefficient.
↵† n = 103 in 10 mg/kg group.
↵‡ n = 86, 92, and 95 in 3, 6, and 10 mg/kg groups, respectively. W14: Week 14; IFX: infliximab; W6: Week 6; HAQ: Health Assessment Questionnaire; ΔTSS: change in total modified Sharp score; W54: Week 54; SDAI: Simplified Disease Activity Index; TJC28: tender joint count in 28 joints; SJC28: swollen joint count in 28 joints; CRP: C-reactive protein; PtGA: patient’s global assessment; PGA: physician’s global assessment; W10: Week 10; DAS28: 28-joint Disease Activity Score.